Published in J Allergy Clin Immunol on January 01, 1976
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Bee venom phospholipase A2 induces a primary type 2 response that is dependent on the receptor ST2 and confers protective immunity. Immunity (2013) 1.88
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 1.29
Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. J Clin Invest (2011) 1.16
Bee Venom Phospholipase A₂: Yesterday's Enemy Becomes Today's Friend. Toxins (Basel) (2016) 0.88
Purification and characterization of two new allergens from the venom of Vespa magnifica. PLoS One (2012) 0.88
Bee venom phospholipase A2 suppresses allergic airway inflammation in an ovalbumin-induced asthma model through the induction of regulatory T cells. Immun Inflamm Dis (2015) 0.83
Investigative studies of the dermatitis caused by the larva of the brown-tail moth, Euproctis chrysorrhoea l. (Lepidoptera, Lymantriidae). III. Chemical analysis of skin reactive substances. Arch Dermatol Res (1977) 0.80
Therapeutic Effects of Bee Venom on Immunological and Neurological Diseases. Toxins (Basel) (2015) 0.80
Evaluation of Phototoxic and Skin Sensitization Potentials of PLA 2 -Free Bee Venom. Evid Based Complement Alternat Med (2015) 0.76
Bee Venom Phospholipase A2 Ameliorates House Dust Mite Extract Induced Atopic Dermatitis Like Skin Lesions in Mice. Toxins (Basel) (2017) 0.75
Insect-sting encephalopathy. Br Med J (Clin Res Ed) (1982) 0.75
Retained bee stinger in the tarsal plate. Int Ophthalmol (2011) 0.75
Purification and properties of the replicative intermediate of the RNA bacteriophage R17. Proc Natl Acad Sci U S A (1966) 7.55
Ragweed immunotherapy in adult asthma. N Engl J Med (1996) 4.69
Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science (1968) 4.38
Modulation of inflammation and immunity by cyclic AMP. Science (1974) 4.31
The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol (1993) 3.75
Urinary tract infection caused by Staphylococcus saprophyticus. J Infect Dis (1980) 3.67
The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes. J Immunol (1972) 3.51
Evidence for individual human peripheral blood lymphocytes bearing both B and T cell markers. Nature (1974) 3.12
Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol (1997) 2.91
Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. N Engl J Med (2016) 2.89
Pharmacologic control of allergic histamine release in vitro: evidence for an inhibitory role of 3',5'-adenosine monophosphate in human leukocytes. J Immunol (1972) 2.70
A reappraisal of sting challenges: to whom should we offer venom immunotherapy? J Allergy Clin Immunol (1994) 2.65
Anaphylaxis. N Engl J Med (1991) 2.53
Histamine augments leukocyte adenosine 3',5'-monophosphate and blocks antigenic histamine release. Science (1971) 2.47
Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol (2001) 2.38
Mediator release after nasal airway challenge with allergen. Am Rev Respir Dis (1983) 2.37
The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med (1990) 2.35
A case for venom treatment in anaphylactic sensitivity to hymenoptera sting. N Engl J Med (1974) 2.33
Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res (1993) 2.24
Inhibition of histamine release by histamine controlled by H2 receptor. Nature (1973) 2.19
IL-13 expression at the sites of allergen challenge in patients with asthma. J Immunol (1995) 2.18
Immunological aspects of allergic asthma. Annu Rev Immunol (1994) 2.17
Effects of cholera enterotoxin on adenosine 3',5'-monophosphate and neutrophil function. Comparison with other compounds which stimulate leukocyte adenyl cyclase. J Clin Invest (1973) 2.16
Discontinuing venom immunotherapy: outcome after five years. J Allergy Clin Immunol (1996) 2.13
Tuberculin-active carbohydrate that induces inhibition of macrophage migration but not lymphocyte transformation. Science (1970) 2.12
A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med (1978) 2.08
Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol (2000) 2.05
Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest (1983) 2.05
Socioeconomic status and race as risk factors for cockroach allergen exposure and sensitization in children with asthma. J Allergy Clin Immunol (1996) 2.03
The effects of the H1 and H2 antihistamines on "allergic" histamine release and its inhibition by histamine. J Pharmacol Exp Ther (1975) 2.02
Genomic organization, chromosomal localization, and independent expression of human cyclin D genes. Genomics (1992) 1.99
Histamine release from human leukocytes: studies with deuterium oxide, colchicine, and cytochalasin B. J Clin Invest (1972) 1.98
Molecular identification of an IgE-dependent histamine-releasing factor. Science (1995) 1.95
Effects of cholera toxin on in vitro models of immediate and delayed hypersensitivity. Further evidence for the role of cyclic adenosine 3',5'-monophosphate. J Clin Invest (1973) 1.94
Rectal colonization with group B streptococcus: relation to vaginal colonization of pregnant women. J Infect Dis (1977) 1.94
The immediate allergic response: in vitro separation of antigen activation, decay and histamine release. J Immunol (1971) 1.93
Anaphylactic release of thromboxane A2, prostaglandin D2, and prostacyclin from human lung parenchyma. Am Rev Respir Dis (1981) 1.86
Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med (1985) 1.84
Clinical and in vitro studies on the role of immunotherapy in ragweed hay fever. Am J Med (1968) 1.84
Epidemiology of insect venom sensitivity. JAMA (1989) 1.83
Role of hand contamination of personnel in the epidemiology of gram-negative nosocomial infections. J Pediatr (1975) 1.81
Immunologic and cellular changes accompanying the therapy of pollen allergy. J Clin Invest (1971) 1.80
Human lung mast cells: purification and characterization. J Immunol (1982) 1.78
The role of cyclic AMP in the cytolytic activity of lymphocytes. J Immunol (1971) 1.78
Generation of leukotrienes by purified human lung mast cells. J Clin Invest (1982) 1.77
The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release. J Immunol (1971) 1.73
House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol (2001) 1.73
Release of slow reacting substance of anaphylaxis (SRS-A) from human leukocytes by the calcium ionophore A23187. J Immunol (1976) 1.72
IgE receptors on human basophils. Relationship to serum IgE concentration. J Clin Invest (1978) 1.71
IgE responses in human filariasis. I. Quantitation of filaria-specific IgE. J Immunol (1981) 1.71
Basophil "releasability" in patients with asthma. Am Rev Respir Dis (1980) 1.70
Replication of bacteriophage ribonucleic acid: some physical properties of single-stranded, double-stranded, and branched viral ribonucleic acid. J Virol (1967) 1.69
Ultrastructure of Escherichia coli cells infected with bacteriophage R17. J Bacteriol (1966) 1.68
Polyribosomes of Escherichia coli. I. Effects of monovalent cations on the distribution of polysomes, ribosomes and ribosomal subunits. J Mol Biol (1969) 1.67
The effects of a series of prostaglandins on in vitro models of the allergic response and cellular immunity. Prostaglandins (1972) 1.67
Structure and synthesis of a lipid-containing bacteriophage. X. Improved techniques for the purification of bacteriophage PM2. Virology (1972) 1.66
Physiologic manifestations of human anaphylaxis. J Clin Invest (1980) 1.65
Studies on the mechanism of lymphocyte-mediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. J Immunol (1973) 1.63
Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy (2001) 1.63
Measurement of IgE on human basophils: relation to serum IgE and anti-IgE-induced histamine release. J Immunol (1977) 1.63
Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine. N Engl J Med (1989) 1.62
Numerical diagnostic key for the identification of Enterobacteriaceae. Appl Microbiol (1972) 1.61
A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet (1987) 1.60
IgE antibody measurements in ragweed hay fever. Relationship to clinical severity and the results of immunotherapy. J Clin Invest (1973) 1.58
Routine use of penicillin skin testing on an inpatient service. N Engl J Med (1971) 1.58
Natural history of Hymenoptera venom sensitivity in adults. J Allergy Clin Immunol (1997) 1.55
Identification of Salmonella with the O-1 bacteriophage. Appl Microbiol (1974) 1.54
The radioallergosorbent test: Uses and abuses. J Allergy Clin Immunol (1980) 1.54
Structure and synthesis of a lipid-containing bacteriophage. 3. Purification of bacteriophage PM2 and some structural studies on the virion. Virology (1969) 1.54
Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther (2000) 1.54
High-titer protamine-specific IgG antibody associated with anaphylaxis: report of a case and quantitative analysis of antibody in vasectomized men. Anesthesiology (1993) 1.54
Activation of resting T lymphocytes by anti-CD3 (T3) antibodies in the absence of monocytes. J Immunol (1985) 1.53
Replication of bacteriophage ribonucleic acid: alterations in polyribosome patterns and association of double-stranded RNA with polyribosomes in Escherichia coli infected with bacteriophage R17. Proc Natl Acad Sci U S A (1967) 1.52
Interaction of non-lytic beta-lactams with penicillin-binding proteins in Streptococcus pneumoniae. J Gen Microbiol (1987) 1.52
Structure and synthesis of a lipid-containing bacteriophage. I. Growth of bacteriophage PM2 and alterations in nucleic acid metabolism in the infected cell. Virology (1969) 1.52
Identification of basophil granulocytes as a site of allergic histamine release. J Immunol (1972) 1.52
Replication of bacteriophage RNA: some properties of the parental-labeled replicative intermediate. J Mol Biol (1965) 1.51
In vitro studies of human reaginic allergy. Adv Immunol (1968) 1.50
Ocular manifestations of graft-vs-host disease. Ophthalmology (1983) 1.50
Natural rubber latex skin testing reagents: safety and diagnostic accuracy of nonammoniated latex, ammoniated latex, and latex rubber glove extracts. J Allergy Clin Immunol (1996) 1.49
Antigenic and allergenic changes during storage of a pollen extract. J Allergy Clin Immunol (1982) 1.49
Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol (1992) 1.48
Arachidonic acid metabolism in purified human lung mast cells. J Immunol (1984) 1.47
Diagnosis of natural rubber latex allergy: multicenter latex skin testing efficacy study. Multicenter Latex Skin Testing Study Task Force. J Allergy Clin Immunol (1998) 1.47
Immediate hypersensitivity reactions to penicillin and related antibiotics. Clin Allergy (1988) 1.47
Antigen-specific IgE and IgA antibodies in bronchoalveolar lavage fluid are associated with stronger antigen-induced late phase reactions. Clin Exp Allergy (2001) 1.46
Effect of in vitro aspirin stimulation on basophils in patients with aspirin-exacerbated respiratory disease. Clin Exp Allergy (2009) 1.46
The mechanism of basophil histamine release induced by antigen and by the calcium ionophore A23187. J Immunol (1975) 1.45
Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest (1985) 1.45
Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor. J Allergy Clin Immunol (1991) 1.45